Compare OPTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTX | ZNTL |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.9M | 289.0M |
| IPO Year | 2021 | 2020 |
| Metric | OPTX | ZNTL |
|---|---|---|
| Price | $5.28 | $1.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 353.9K | ★ 1.3M |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $1.21 |
| 52 Week High | $14.92 | $6.95 |
| Indicator | OPTX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.46 | 28.82 |
| Support Level | $5.03 | N/A |
| Resistance Level | $8.85 | $2.76 |
| Average True Range (ATR) | 0.57 | 0.17 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 5.31 | 4.76 |
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining. Syntec Optics focuses on four end markets of defense, medical, consumer, and communications all with several mission-critical applications.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.